Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Emergency PWAS in Respiratory Infectious Disease

A legfontosabb adatok

Ki végzi
The University of Hong Kong
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
2000 fő, tervezett
Kezdés
2023. ápr. 11.
Várható befejezés
2028. máj. 1.
A vizsgálat típusa
Megfigyeléses, 7 csoport
A vizsgált kezelések
  • Biomarker blood draw and saliva collection
A regiszteradat frissítve
2026. május 12.

Ki vehet részt

Életkor
18 év – 100 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients eligible for enrolment include:
  • With reference to previous inclusion criteria are:
  • Adults ≥18 years of age; AND
  • Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)*; AND
  • Informed consent; Note: scaRID is defined according to ALL three criteria:
  • Community acquired (not hospitalised for <28 days); AND
  • Acute infection (defined as symptom onset <8 days and any ONE of reported fever or chills or aural temperature >37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND
  • Probable respiratory infection - According to any ONE of:; new cough or new sputum production or; chest pain or; dyspnoea or; tachypnoea or; abnormal lung examination or; respiratory failure; or; physician's judgment (presenting with systemic or gastrointestinal symptoms); Control subjects will be drawn from two groups:
  • The worried well - adult patients with a National Early Warning Score (NEWS) <3 and a temperature <37.5°C
  • Relatives or accompanying friends with no acute illness

Ki nem vehet részt

  • Solid organ or haematopoietic stem-cell transplant within the previous 90 days
  • Skin or orthopaedic infections
  • Urinary tract infection
  • Sexual transmitted disease
  • Human immunodeficiency virus (HIV) infection
  • Active graft-versus-host disease or bronchiolitis obliterans
  • Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases
  • Stroke
  • Refusal of consent
  • Recent hospitalisation (<28 days)
  • Enrolled in another clinical trial
  • Cellulitis
  • Acute abdominal sepsis
  • Immunocompromised/potential neutropenic fever
  • Toxidrome
  • Non-organic acute psychosis

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 100 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID).

A teljes eredeti leírásKevesebb

Phase 1

1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2 2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics

A vizsgálat 7 csoportja

  • Viral infection

    Viral infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree

    Kezelés: Biomarker blood draw and saliva collection

  • Bacterial infection

    Bacterial infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).

    Kezelés: Biomarker blood draw and saliva collection

  • Viral-Viral co-infection

    Viral-viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).

    Kezelés: Biomarker blood draw and saliva collection

  • Bacterial-Viral co-infection

    Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).

    Kezelés: Biomarker blood draw and saliva collection

  • Fungal-Mycobacterium co-infection

    Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).

    Kezelés: Biomarker blood draw and saliva collection

  • Infection of uncertain origin

    Infection of uncertain origin subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).

    Kezelés: Biomarker blood draw and saliva collection

  • Control Subjects

    Control group subjects, if they agree, will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms (if applicable); and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if applicable); and c) 48 hours +/- 6 hours from symptom onset (if applicable).

    Kezelés: Biomarker blood draw and saliva collection

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Emergency PanorOmic Wide Association Study in Respiratory Infectious Disease (ePWAS-RID)
Kérdések a feltételekről
Forrás: NCT05336851: ki vehet részt
A regiszteradat frissítve
2026. május 12.